Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Excision of a Large Gastrointestinal Stromal Tumour Following 16 Months of Neoadjuvant Therapy with Imatinib (Case Report)

Excision of a Large Gastrointestinal Stromal Tumour Following 16 Months of Neoadjuvant Therapy... Oncol Ther (2019) 7:159–164 https://doi.org/10.1007/s40487-019-00101-4 CASE REPORT Excision of a Large Gastrointestinal Stromal Tumour Following 16 Months of Neoadjuvant Therapy with Imatinib (Case Report) . . . Fousseni Alassani Boyodi Tchangai Aklesso Bagny . . . Ablavi A. Adani-Ife Kossigan A. Amavi Tchin Darre Komla Attipou Received: August 23, 2019 / Published online: November 2, 2019 The Author(s) 2019 shown to be effective in several studies, but the ABSTRACT duration of this treatment is still a subject of debate. Introduction: Although the standard treatment Case report: We report a case of a large GIST of for stromal tumours is surgery, in locally the stomach in a 51-year-old patient with advanced forms, it is often necessary to achieve atypical presentation that was initially unre- tumour downstaging to improve surgical out- sectable. Neoadjuvant treatment with imatinib comes. Neoadjuvant treatment in gastrointesti- for 16 months resulted in a good response, nal stromal tumours (GISTs) with tyrosine allowing secondary surgical excision. kinase inhibitors, including imatinib, has been Conclusion: Imatinib in neoadjuvant therapy should be continued as long as there is a good Enhanced digital features To view enhanced digital features for this article go to https://doi.org/10.6084/ response and tolerance to the medication to http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Excision of a Large Gastrointestinal Stromal Tumour Following 16 Months of Neoadjuvant Therapy with Imatinib (Case Report)

Loading next page...
 
/lp/springer-journals/excision-of-a-large-gastrointestinal-stromal-tumour-following-16-K4sk4sPlum
Publisher
Springer Journals
Copyright
Copyright © 2019 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-019-00101-4
Publisher site
See Article on Publisher Site

Abstract

Oncol Ther (2019) 7:159–164 https://doi.org/10.1007/s40487-019-00101-4 CASE REPORT Excision of a Large Gastrointestinal Stromal Tumour Following 16 Months of Neoadjuvant Therapy with Imatinib (Case Report) . . . Fousseni Alassani Boyodi Tchangai Aklesso Bagny . . . Ablavi A. Adani-Ife Kossigan A. Amavi Tchin Darre Komla Attipou Received: August 23, 2019 / Published online: November 2, 2019 The Author(s) 2019 shown to be effective in several studies, but the ABSTRACT duration of this treatment is still a subject of debate. Introduction: Although the standard treatment Case report: We report a case of a large GIST of for stromal tumours is surgery, in locally the stomach in a 51-year-old patient with advanced forms, it is often necessary to achieve atypical presentation that was initially unre- tumour downstaging to improve surgical out- sectable. Neoadjuvant treatment with imatinib comes. Neoadjuvant treatment in gastrointesti- for 16 months resulted in a good response, nal stromal tumours (GISTs) with tyrosine allowing secondary surgical excision. kinase inhibitors, including imatinib, has been Conclusion: Imatinib in neoadjuvant therapy should be continued as long as there is a good Enhanced digital features To view enhanced digital features for this article go to https://doi.org/10.6084/ response and tolerance to the medication to

Journal

Oncology and TherapySpringer Journals

Published: Nov 2, 2019

References